The patent application for biosynthetic heparin in the United States is currently under examination by the United States Patent and Trademark Office (USPTO).
What is Biosynthetic Heparin?
Biosynthetic heparin is a form of heparin produced through biological processes, such as recombinant DNA technology, rather than being extracted from animal tissues. This method aims to create a more consistent, purified, and potentially safer alternative to traditional animal-derived heparin.
Why Pursue Biosynthetic Heparin Patents?
Developing biosynthetic heparin represents a significant scientific advancement, offering potential benefits like reduced risk of contamination and more predictable drug properties. Companies seek patent protection to secure exclusive rights to their novel manufacturing processes, compositions, and uses of this therapeutic agent. This exclusivity allows them to recoup research and development investments and establish market leadership.
How is Biosynthetic Heparin Made?
The production of biosynthetic heparin typically involves genetic engineering of host cells to produce heparin or heparin-like molecules. This can include inserting genes that encode for the enzymes necessary for heparin biosynthesis into bacteria, yeast, or mammalian cell lines. These engineered cells are then cultured under specific conditions to produce the desired product, which is subsequently purified. [1]
What are the Potential Advantages Over Traditional Heparin?
Traditional heparin is derived from animal sources, most commonly porcine intestinal mucosa. This method carries inherent risks, including the potential for viral contamination and batch-to-batch variability. Biosynthetic heparin, by contrast, offers the prospect of a highly purified product with a consistent molecular profile, potentially reducing the risk of immunogenic reactions and ensuring greater therapeutic reliability. [1]
When Does Patent Protection Typically Last?
In the United States, utility patents generally have a term of 20 years from the date on which the application for the patent was filed. However, certain patent term extensions may be available for pharmaceutical products to compensate for regulatory review periods. [2]
Can Companies Challenge This Patent Application?
Third parties can challenge patent applications during the examination process through preissuance submissions, providing prior art that may affect the patentability of the invention. Once a patent is granted, its validity can be challenged in court through patent infringement lawsuits or post-grant review proceedings. [3]
Where Can I Find More Information on Drug Patents?
DrugPatentWatch.com provides a comprehensive database of drug patents, including information on patent applications, granted patents, and patent expiry dates for various pharmaceuticals. [4]
Sources
1. U.S. Patent Application Publication, WO2024065774A1. (Accessed June 12, 2024).
2. United States Patent and Trademark Office. "Patent Basics". (Accessed June 12, 2024).
3. U.S. Department of Justice. "Antitrust Guidance for Patent Assertion Entities". (Accessed June 12, 2024).
4. DrugPatentWatch.com. (Accessed June 12, 2024).